NUMBER-NEEDED-TO-TREAT (NNT) AND COST OF RESPONSES ACHIEVED IN TYROSINE KINASE INHIBITOR (TKI) TREATMENT OF REFRACTORY CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN THE UNITED STATES (US)

Levy M. Y.; McGarry L.; Iannazzo S.; Huang H.; Chiroli S.

首页> 外文期刊>Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research >NUMBER-NEEDED-TO-TREAT (NNT) AND COST OF RESPONSES ACHIEVED IN TYROSINE KINASE INHIBITOR (TKI) TREATMENT OF REFRACTORY CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN THE UNITED STATES (US)

【24h】

NUMBER-NEEDED-TO-TREAT (NNT) AND COST OF RESPONSES ACHIEVED IN TYROSINE KINASE INHIBITOR (TKI) TREATMENT OF REFRACTORY CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN THE UNITED STATES (US)

机译：酪氨酸激酶抑制剂（TKI）治疗难治性慢性相慢性骨髓白血病（美国CP-CML）的抑制作用（NNT）和响应成本。（美国）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research》 |2017年第5期|共1页
作者
Levy M. Y.; McGarry L.; Iannazzo S.; Huang H.; Chiroli S.;
展开▼
作者单位

Baylor Univ Med Ctr Dallas TX USA;

ARIAD Pharmaceut Inc Cambridge MA 02139 USA;

SIHS Hlth Econ Consulting Turin Italy;

ARIAD Pharmaceut Inc Cambridge MA 02139 USA;

INCYTE Epalinges Switzerland;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类预防医学、卫生学;
关键词

相似文献

外文文献
中文文献
专利

1. NUMBER-NEEDED-TO-TREAT (NNT) AND COST OF RESPONSES ACHIEVED IN TYROSINE KINASE INHIBITOR (TKI) TREATMENT OF REFRACTORY CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN THE UNITED STATES (US) [J] . Levy M. Y., McGarry L., Iannazzo S., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017,第5期

机译：酪氨酸激酶抑制剂（TKI）治疗难治性慢性相慢性骨髓白血病（美国CP-CML）的抑制作用（NNT）和响应成本。（美国）
2. Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia [J] . Carsten Hirt, Sergio lannazzo, Silvia Chiroli, Applied health economics and health policy . 2019,第4期

机译：第三代酪氨酸激酶抑制剂（TKI）Ponatinib，与第二代TKIS或干细胞移植的成本效果，作为慢性相慢性髓性白血病的第三线治疗
3. Can Chronic-Phase Chronic Myeloid Leukemia Patients Achieve Optimal and Durable Responses after Two Failed TKI Treatments? Real-World Evidence Data [J] . Breccia Massimo Acta Haematologica . 2019,第2期

机译：慢性相慢性骨髓性白血病患者可以在两次失败的TKI治疗后实现最佳和耐用的反应吗？现实世界证据数据
4. Novel Inhibitors of T315I Mutant BCR-ABL1 Tyrosine Kinase for Chronic Myeloid Leukemia Disease Through Fragment-Based Drug Design [C] . Satya Anindita, Atika Marnolia, Hersal Hermana Putra, International symposium on bioinformatics research and applications . 2018

机译：T315I突变BCR-ABL1酪氨酸激酶的新型抑制剂通过基于片段的药物设计治疗慢性粒细胞白血病
5. Tyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia: Long-Term Patient Care and Management [O] . Stephanie Bauer1, Susan Buchanan2, Irene Ryan3 2016

机译：酪氨酸激酶抑制剂治疗慢性粒细胞性白血病：长期的患者护理和管理
6. BCR-ABL1transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors [O] . Hye-young Song, Hayeon Noh, Soo young Choi, 2018

机译：4周的BCR-ABL1Transcript水平对多种酪氨酸激酶抑制剂治疗的慢性相慢性髓性白血病患者预测慢性相慢性骨髓性白血病患者的存活具有预后意义

NUMBER-NEEDED-TO-TREAT (NNT) AND COST OF RESPONSES ACHIEVED IN TYROSINE KINASE INHIBITOR (TKI) TREATMENT OF REFRACTORY CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN THE UNITED STATES (US)

著录项

相似文献

相关主题

期刊订阅